---
schema_version: "secwatch.filing_event.v1"
accession: "0001021771-21-000087"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:25:59.797250+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioRestorative Therapies prices $23M public offering, uplists to Nasdaq; appoints CFO and new directors

## Summary
- Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.
- Common stock begins trading on Nasdaq Capital Market under symbol BRTX on November 5, 2021.
- Appointed Robert E. Kristal as CFO; granted option for 10,490 shares at $13.50; also elected Patrick F. Williams and David Rosa as directors.
- Granted options to officers and directors: Alstodt and Silva each received 42,059 shares; also repriced their existing options from $47.60 to $13.50.
- Intends to use proceeds for clinical trials of BRTX-100, ThermoStem R&D, and working capital.

## SEC filing metadata
- accession: 0001021771-21-000087
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/form8kdtd110421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001021771-21-000087
- JSON: https://secwatch.observer/filing/0001021771-21-000087.json
- Plain text: https://secwatch.observer/filing/0001021771-21-000087.txt

## Key facts
- Executive change
  David Rosa was elected as Director at BioRestorative Therapies, Inc..
  - Action: elected
  - Role: Director
  source text: Effective November 4, 2021, David Rosa was elected a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm
- Executive change
  Patrick F. Williams was elected as Director at BioRestorative Therapies, Inc..
  - Action: elected
  - Role: Director
  source text: Effective November 4, 2021, Patrick F. Williams was elected a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm
- Executive change
  Robert E. Kristal was appointed as Chief Financial Officer at BioRestorative Therapies, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective November 4, 2021, Robert E. Kristal, age 54, was appointed Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.